Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported) February 17, 2005

 

 

REGENERATION TECHNOLOGIES, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware   0-31271   59-3466543

(State or Other Jurisdiction

of Incorporation)

   (Commission File Number)  

(IRS Employer

Identification No.)

 

11621 Research Circle, Alachua, Florida   32615
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (386) 418-8888

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Item 2.02. Results of Operations and Financial Condition.

 

On February 17, 2005, Regeneration Technologies, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2004. The Company also announced that it had retained Lehman Brothers to explore strategic alternatives available to the Company. A copy of this press release is furnished herewith as Exhibit 99.1.

 

The information in this Current Report, including the news release attached hereto, is being furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended, or otherwise subject to liabilities of that Section.

 

Item 9.01 Financial Statements and Exhibits.

 

(c) Exhibits.

 

  99.1 Press Release dated February 17, 2005.

 

2

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    REGENERATION TECHNOLOGIES, INC.
Date: February 17, 2005   By:  

/s/ Thomas F. Rose

    Name:   Thomas F. Rose
    Title:   Vice President and Chief Financial Officer

 

 

3

EXHIBIT INDEX

 

99.1     Regeneration Technologies, Inc. press release dated February 17, 2005.